Jaguar Health, Inc. (JAGX) Earnings Call Transcript
November 17, 2026
Earnings Call Speaker Segments
Thank you, Sherry. And thanks to everyone for being on the investor webcast today. As you've heard, I'm Lisa Conte. I serve as founder, president, and CEO of Jaguar Health along with our wholly owned subsidiary, Napo Pharmaceuticals. I also chair our Italian subsidiary, Napo Therapeutics. As is my habit, I may refer to Jaguar and Napo interchangeably when talking about the company. Once I finish my remarks today, Carol Lizak, our CFO, will walk through a recap of the financial highlights for the third quarter of 2026. One key highlight I want to call out: Jaguar cut its outstanding debt balance substantially, by more than $10 million, during the third quarter of 2026. Once more, what we're focusing on in today's webcast is near-term catalysts that can transform the business and a sharply defined strategic direction. Those of you who have followed this company before might recall that back in January of 2026 we completed a deal we consider transformative — signing a U.S. commercial out-license agreement with Future Pak for Mytesi, which is the brand name of our FDA-approved crofelemer formulation intended for adults with HIV/AIDS and diarrhea. Included under that license as well was Canalevia-CA1, our crofelemer formulation holding conditional FDA approval for dogs experiencing chemotherapy-induced diarrhea. Our first reason for deciding strategically to out-license Mytesi to Future Pak was that they had just bought Theratechnologies, a commercial HIV company whose U.S. commercial effort is over four times larger than Jaguar's. They work entirely in the U.S. HIV space and have additional HIV-related products. Second, this satisfied our strategic plan of bringing in significant non-dilutive capital to help fund our intense development focus on our late-stage clinical program for a novel proprietary powder for oral solution formulation of crofelemer. The key point about the novel formulation is that it is a separate product, an entirely different business structure of crofelemer, aimed specifically at rare intestinal failure indications. Identical active ingredient and identical product, with specific production steps shared by Mytesi, but a separate formulation aimed at uncommon intestinal failure uses. Uncommon in the sense that we possess orphan drug status for those intestinal failure uses—two separate uses across both the US and Europe. Jaguar and Napo still make Mytesi and Canalevia-CA1, so they supply those products to Future Pak under a cost-plus arrangement, which keeps that as a profit center. But today we are entirely a rare disease GI company, with all of our human development work tightly and deliberately concentrated on this rare disease program. For many years before we signed the out-license deal with Future Pak, we were selling Mytesi down through the distributors, and we had a sales force promoting directly to the physicians who prescribed Mytesi to patients — along with the expense that came with that, and the expense that comes with having just one product, unlike the Theratech situation we have right now. At the moment, we're operating as a Mytesi supplier to Future Pak, which means the way we report sales and revenue looks quite different, and the same is true for how the non-dilutive dollars from that agreement are affected. Coming back to our core strategic focus: our endgame strategy is still centered on evaluating strategic alternatives, and that's driven by the enormous value a potential development and commercialization partner would see in our rare disease intestinal failure program — our late-stage rare disease intestinal failure program. For context, the out-license to Future Pak amounted to $18 million upfront, mainly for the U.S. HIV market, where the peak annual opportunity is perhaps $50 million to $70 million each year. Third-party market research indicates that by 2033, the global short bowel syndrome market—covering our bowel syndrome with intestinal failure along with certain rare congenital disorders—is expected to surpass $8 billion. A separate piece of third-party research values the worldwide MVID marketplace alone—an ultra-rare indication that has no treatments and nothing in clinical development—at over $2 billion by 2032. As before, our strategic goal is to secure non-dilutive capital from a strategic partner, following the model of our Future Pak arrangement for Mytesi. The market sizes differ enormously: Mytesi in U.S. HIV runs in the tens of millions, whereas intestinal failure worldwide reaches into the billions. I just referred to MVID, which stands for pediatric microvillus inclusion disease—as I said, an extremely uncommon condition with no treatments approved and a fatal course. Within the intestinal failure program, this is Jaguar's value driver for the very near term. It's the lead indication we're targeting; enrollment is complete in a pivotal trial—a blinded pivotal trial—that will support a targeted new drug application submission in mid-2027. That's about eight, nine, 10 months away; this is really exciting and meaningful for MVID patients, for the devastating effect on their health, and for the toll on their families and other supportive caregivers, and MVID patients have many of those. With increasing awareness of how crofelemer has affected our compassionate use patients—data that has been published and presented at multiple medical conferences—we have received numerous inquiries from patients and physicians regarding the potential for future access to crofelemer. Short bowel syndrome, which you will hear me refer to as SBS or SBS-IF, meaning short bowel syndrome with intestinal failure, represents a larger follow-on indication that employs the identical dosage formulation and the same physiological mechanism for intestinal failure as seen in MVID patients. SBS and MVID each hold separate rare disease orphan designations, both within the U.S. and Europe. Our intestinal failure program is a blockbuster global market opportunity, first and foremost when it comes to addressing the catastrophic unmet medical need in patients — blockbuster in terms of the beneficial impact on morbidity and mortality and on the cost to the healthcare system, and then also the financial return opportunity for all stakeholders, including our shareholders. That return opportunity, of course, matters especially for the motivation and incentive of potential corporate partners and strategic alternatives that we are looking at. As I mentioned, the global market for SBS-IF is estimated at over $8 billion, again by a third party in 2033, with MVID over $2 billion. Let me spend a moment on more than just the dollar figures — on how devastating intestinal failure is for patients, and what that means for the community of caregivers around them: family members, healthcare professionals, nurses, nutritionists, and others. Managing these situations truly takes a village. Intestinal failure is a debilitating condition that frequently means patients must get life-sustaining fluids and electrolytes, along with IV delivery of the nutrients life depends on — all of which falls under something known as TPN, or total parenteral nutrition. When total parenteral nutrition is combined with supplemental fluids, it's called parenteral support; that's IV nutritional support — IV nutritional support. A great many intestinal failure patients need this parenteral support for as much as 20 hours a day, seven days a week. IV nutrition. Clearly, this is a devastating circumstance for the patient—both in terms of health care and the plain effect on their quality of life.
Parenteral support keeps these patients alive—it's essential, it's their nourishment—but it comes with fairly severe complications: toxicity to the liver and kidneys, impaired cognitive function, negative effects on growth, infections, and line infections from receiving IV nutrition, and in the end, not only all that morbidity but mortality too. That's the reason standard-of-care parenteral support, TPN, gets described as a lethal natural history for these patients. The expense is also substantial; in the United States it's estimated at roughly $500,000 per patient annually, and the burden on the healthcare system is unavoidably larger—it can exceed $1 million per patient per year because of infectious complications and the work of keeping that balance of life-sustaining nutrients correct. And all of this sits on top of the mortality risk. MVID is congenital, so the patient—the infant, the baby—is born with profuse diarrhea and cannot absorb the nutrients of life. When the newborn isn't diagnosed right away, they frequently die immediately. When the newborn is diagnosed, they'll remain on parenteral support for the rest of their life. Again, as much as seven days a week, 20 hours a day. What we're aiming for in giving these patients adjunctive therapy is a decrease in how much time they spend on parenteral support. Parenteral support keeps these patients alive, yet the real question is whether we can reduce the hours devoted to it—and in doing so, meaningfully affect the severe toxicities and comorbidities that cut life short for them, and here, for these infants. Even a 5%-10% decrease would qualify as clinically meaningful. Remember, we're talking about infants; allowing the baby to grow into a child and thrive alters life and alters the disease, and alters things for the family's circumstances too. So the endpoint in the crofelemer clinical development program is, in fact, the reduction in parenteral support. Let's say even 10%-15%. So the patient could receive a meaningful portion of their parenteral support overnight, during sleep, which helps them keep some quality of life and the ability to go to school while awake. They wouldn't need to remain connected to an IV in order to do certain routine daily activities, and that naturally reduces the circumstances and the setting that create infection risk as well. Keeping in mind how significant that 5%, 10%, 15% figure is, last June we shared pivotal data at the 58th Annual European Society for Pediatric Gastroenterology, Hepatology, and Nutrition meeting. It was held in Lille, France, and goes by the name ESPGHAN. In that presentation, for one MVID patient, weekly parenteral support needs adjusted for body weight fell by as much as 48%. Keep in mind that 10%-15% is considered clinically meaningful. That 48% came after over 12 months on crofelemer with no safety problems. We also presented two pediatric patients with short bowel syndrome IF, and their PS requirements adjusted for body weight went down by up to 40%, again across more than a year of treatment with no safety issues. These results are stunning. It's difficult to convey how much this matters clinically and how fulfilling it is for everyone involved to watch these patients—these kids—doing well, and it explains the growing awareness within the intestinal failure community. Another really striking aspect was that once these patients had been on treatment for roughly three months, the protocol called for taking them off crofelemer, and they relapsed right away and had to resume crofelemer—one of the most compelling trial design elements for showing a product's genuine efficacy. So these patients have been receiving treatment for more than a year at this point, and our expectation is that they will remain on crofelemer for the remainder of their lives — and it's a genuine point of pride and honor for us to supply the product for that. We have not seen any safety issues tied to crofelemer among our intestinal failure patients, or in any patient we've treated with anything, and that lines up very well with what's been observed for crofelemer across thousands of patients, whether in clinical trials or through access to the product as it's now commercialized. This safety profile is a hallmark of crofelemer, and we should never take it for granted, since a safety issue is one of the most common reasons that new drug applications fail. Just to remind everyone, the FDA is the body that approves drugs. It evaluates new drug applications and grants approval based on benefit versus risk. If there's no risk at all, then the benefit lasts forever. Within the program, beyond those compassionate use or expanded access efforts—which go by various names we've shared—we've also finished enrolling patients in a blinded clinical trial for MVID. That trial is running at sites in the U.S., Italy, and the UAE—the United Arab Emirates, that is, in Dubai and Abu Dhabi. To back the planned NDA submission for patients in this trial, we filed an amendment, and the FDA did grant us authorization for a treatment-only extension phase following the placebo portion of the study. That was announced this past September. Every randomized pediatric MVID patient in this trial has now entered the single-blind extension phase and is currently receiving crofelemer. It's the powder for oral solution, given as adjunctive therapy to their parenteral support, which lets patients benefit from the product and lets us gather additional safety data — very important for a new drug application — along with continued efficacy. Drawing on information from patients in this extension as well as the early access compassionate use patients referenced earlier—data that has already been presented—we see a new drug application opportunity for MVID, that ultra-rare disease, around mid-2027, involving roughly 3%-4% of the patient population, which is the usual treatment share across virtually any indication in clinical trials, pivotal drug trials; for us that is literally a single-digit count of patients, and it demonstrates how efficient orphan drug indications and ultra-rare indications are. In 2027 as well, we intend to file with the FDA for breakthrough therapy designation for crofelemer for MVID in the U.S. Should the FDA grant that designation, we would have a chance at a review of perhaps only four months once the new drug application is filed, which could allow the product to be approved at the end of 2027. Now I'll turn to the adult patient program. At last month's American College of Gastroenterology Annual Scientific Meeting, positive preliminary results were presented by an investigator for the ongoing open-label third-party pilot study of crofelemer — the same powder for oral solution — in adults with type 1 short bowel syndrome with intestinal failure. Intestinal failure in short bowel syndrome is the same clinical situation as intestinal failure in MVID children. People with short bowel syndrome are unable to take in life-sustaining nutrients, simply because their bowel is short—there's insufficient surface area. A healthy intestine measures roughly 20 to 25 feet.
A short bowel syndrome with intestinal failure, or SBS-IF, intestine might measure five feet or less. Those patients likewise wind up needing parenteral support, once more as much as 20 hours per day, seven days a week, facing the same comorbidities tied to that TPN parenteral support and the same catastrophic toxicities I described earlier in the MVID patients. That is a consequence of the TPN and the parenteral support. Beyond that, we currently have underway a phase II randomized double-blind placebo-controlled trial using this formulation of crofelemer, the identical one used in MVID, running at multiple sites in Germany and Italy for SBS-IF in adults. SBS-IF remains an orphan indication, even though its patient population is larger than MVID's. MVID is caused by congenital abnormalities. Similarly, SBS can result from congenital abnormalities, though it may also arise from surgical removal due to Crohn's disease, ischemia, or cancer. About one-third of patients are accounted for by cancer. Trauma and accidents play a role too. Adults and children with SBS-IF must also deal with long-term dependence on parenteral support, plus the associated risks of morbidity and mortality. In the U.S., roughly 12,000 individuals make up that population. The NDA for MVID—specifically MVID—targets mid-2027, as I mentioned, and we expect this submission to line up with the time the results become available, the unblinding of results from the phase II trial in adults with short bowel syndrome. MVID is a key milestone on the path we've laid out toward eventually getting crofelemer approved for SBS. That matters greatly—above all for patients, so those infants can benefit and get access to MVID treatment, but also for the company's plan to move into a blockbuster indication where no other treatments exist and the unmet medical need is dramatic. The safety data would be the same for MVID and SBS. Manufacturing would also be the same, because it's one formulation. A first approval for MVID—this possible approval for MVID, again, the stepping stone into SBS—would tackle the two most frequent reasons NDAs fail. Competitively speaking, there is nothing available for MVID. Nothing is in development either. For these patients, there's nothing out there except parenteral support, and of course this would be adjunctive to that life-sustaining parenteral support, but hopefully in a way that's more manageable. In SBS, there is an approved product. It's called a GLP-2 approach—not GLP-1; that's the weight loss thing. GLP-2 is basically a growth hormone, and its mechanism tries to grow the intestine somewhat so that parenteral support can be reduced by perhaps 10%-15%. If you recall, those numbers are what's considered clinically irrelevant. Again, we far exceeded that reduction with the 40%-45% seen in both the MVID and the short bowel syndrome compassionate use expanded access patients already reported. GLP-2 growth hormone isn't the standard of care for SBS. Roughly 5% to 7% of patients receive it. It carries a great many side effects, and it is a growth hormone. You can't give a growth hormone, for example, to cancer patients. Stimulating growth is not something you want in a hyperproliferative abnormal condition, and about one-third of short bowel syndrome patients have cancer. Even so, the achievement of GLP-2s was to establish a business model and a regulatory approval benchmark. In the U.S., GLP-2s are reimbursed at around $500,000 per year, and their approval arrived with a clinical benefit of roughly a 10% to 15% reduction in parenteral support. With crofelemer, by contrast, our aim is for it to become standard of care for intestinal failure, starting with MVID, followed by SBS-IF, and in the future there are many other intestinal failure TPN/PS-dependent patient populations. With the clinical proof-of-concept data in hand and the clinical and regulatory milestones coming up in the very near term, we're confident we can achieve our business development goals for the intestinal failure program, move that program forward, and follow the strategy and execution approach we've used before to bring in serious, meaningful, valuable, non-dilutive dollars in line with the size of the market, addressing the serious unmet medical need, driven above all by the benefit and the benefit-risk, with the risk being close to zero, that we provide to patients who have no other treatment option, along with all the business benefits that follow from that. I want to point out that the vast majority of what we do is centered on human health, and naturally, the rare disease program accounts for all of that human focus. That said, we do operate a modest animal health segment, and we're happy to share that Neonorm Dog — that's the name of the product, Neonorm Dog — can now be purchased through Amazon. We anticipate it will be offered before long through additional animal health channels that provide excellent reach, and this represents a truly tremendous chance for pet owners along with veterinarians to obtain animal health products. Neonorm Dog builds on Jaguar's non-prescription Neonorm franchise, taking it into the companion animal space. As it stands, the Neonorm franchise covers Neonorm for foals, horses, foals, and calves. This is a plant-based item meant to help pre-weaned foals and calves stay properly hydrated and maintain bowel health. Neonorm Dog provides a plant-based, non-prescription option that supports normal stool consistency and GI fluid balance in dogs. Regarding Neonorm Dog specifically, we are drawing on the relationships that Jaguar established over the years while we were promoting and educating about Canalevia-CA1, our prescription product for chemotherapy-induced diarrhea in dogs, which is now licensed, promoted, and educated by Future Pak. That's where I'll wrap up on the Neonorm franchise; from this overview, you can tell we're very excited, very enthused, very busy, and very focused on what we're doing, especially with the IF program. I'll now turn things over to our CFO, Carol Lizak, so she can walk you through a summary of the financial highlights — among them the debt reduction we completed during this year's third quarter, which is truly significant and matters a great deal. Carol, the floor is yours.
Okay, thanks Lisa, and I appreciate everyone joining our webcast today. I'll start by walking through the financials for the third quarter of 2026. As Lisa noted, Jaguar signed a U.S. commercial licensing agreement with Future Pak in January 2026. Jaguar is still the manufacturer of Mytesi and Canalevia-CA1, providing those products to Future Pak on cost-plus terms, and it now functions as a distribution entity for Mytesi and Canalevia-CA1, concentrating mainly on research and development work tied to the company's late-stage development program for its powder-for-oral solution formulation of crofelemer for rare disease indications connected to intestinal failure in humans. As we announced in August 2026, Jaguar met the closing conditions needed to receive the non-dilutive holdback payment of roughly $1.8 million, which is part of the upfront fee from Future Pak. In addition, the company recognized license fees of $42,000 during the third quarter of 2026 from a securities purchase agreement with a European partner, backed by a binding term sheet. As of September 30, 2026, total deferred revenue tied to that contract came to $425,000. No federal grant revenue was recognized in the third quarter of 2026 for the clinical study on treating chemotherapy-induced diarrhea in dogs, and 25,520 in the month period ended September 30, 2026. Total net revenue for the company's prescription products came in at about $500,000 in the third quarter of 2026, made up mainly of Mytesi sales at cost plus for Future Pak. Under the royalty-free license agreement with Future Pak, all U.S. revenues generated from Mytesi and Canalevia-CA1, effective January 12, 2026, have been directed to Future Pak. Future Pak is privately held and does not report Mytesi sales. Total net revenue for the company's prescription products in the second quarter of 2026 was approximately $1.2 million. Versus the third quarter of 2025, the number of Mytesi bottles the company sold in this year's third quarter rose significantly, while commercial costs fell substantially. Prescription products net revenue in last year's third quarter, when the company had a sales force and was focused on commercial sales of Mytesi, was roughly $3 million. The loss from operations dropped by $1.2 million, moving from a loss of $7.2 million in the quarter ended September 30, 2025, to a loss of $6 million in the third quarter ended September 30, 2026. That change stemmed mainly from a $700,000 decrease in total net revenue, offset by an operating expense reduction of approximately $2 million attributed to the Future Pak licensing agreement. The net loss shrank by roughly $3.8 million, moving from a $9.6 million loss in the quarter that ended September 30, 2025, to a $5.8 million loss in the quarter ending September 30 of this year. Beyond the operating loss, interest expense rose by $150,000, going from $6,000 of interest income for the quarter ended September 30, 2025, to $156,000 in the quarter ended September 30 this year, driven by interest expenses accrued on notes. The fair value of the financial and hybrid instrument designation under the fair value option, which we refer to as FVO, fell by roughly $2.2 million, from a $2.3 million loss in the quarter ended September 30, 2025, to a $96,000 loss in the same period of 2026. That's mainly because the outstanding carrying amounts of royalty interests and notes payable designated at FVO were lower relative to their fair values, which produced smaller fair value changes during the period. Gain on extinguishment of debt grew by $600,000, up from zero in the three months ended September 30, 2025. That increase came mainly from extinguishing the Streeterville note after the company's exchange transaction, in which the company issued shares of its common stock to Streeterville, leading to full repayment and cancellation of the Streeterville new note. Non-GAAP recurring EBITDA for the third quarters of 2026 and 2025 came to a net loss of approximately $5 million and $9 million, respectively. That wraps up my recap of the high-level financials for the third quarter of 2026. I'll now turn the discussion back over to Lisa. Thank you.
Thanks, Carol. From a strategic standpoint, you should look for business updates before long, since we're still assessing business development along with other strategic alternatives, and those are being driven by the continuing and very near-term catalysts in our rare disease program. That brings today's webcast to a close. We really appreciate you joining us. Many thanks to those who have been with us for quite a while. To everyone in the U.S., I hope you have a wonderful Thanksgiving holiday with your families, and we'll see you next quarter. Bye-bye.
Thank you; this concludes our webcast. You may disconnect at this time.
For developers and AI pipelines
Programmatic access to Jaguar Health, Inc. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.